Understanding Treatment-Resistant Depression: When First-Line Antidepressants Aren't Enough

When a major depressive episode does not improve after the first or second antidepressant prescription, patients and families often ask the same clinical question: is this still depression, or is something else going on? In most cases, the diagnosis has not changed — but the depression has met criteria for treatment resistance, a clinical specifier that meaningfully changes what comes next. This article explains how psychiatrists define treatment-resistant depression (TRD), what the evidence shows about outcomes after sequential medication trials, and which neuromodulation options have FDA clearance for adults who have not responded to standard pharmacotherapy.

What "treatment-resistant" actually means

Treatment-resistant depression is most commonly defined as a major depressive episode that has failed to respond to at least two antidepressant trials of adequate dose and adequate duration — typically a minimum of six weeks at therapeutic dose — within the current episode.¹ TRD is not a separate diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR).² It is a specifier applied to major depressive disorder (MDD) when sequential pharmacotherapy fails to produce adequate response or remission.

Two definitions matter:

• Response means a clinically meaningful reduction in symptom severity — typically a ≥50% drop on a validated rating scale such as the PHQ-9, HDRS, or MADRS.
• Remission means symptom scores have fallen to the non-depressed range (PHQ-9 <5; HDRS ≤7).

A patient may respond without remitting — that is, feel better but still meet partial criteria for depression. The clinical goal is remission, because residual symptoms predict relapse.

Most U.S. payers and most clinical trials use the ≥2-failed-trials threshold; some use ≥3. NeuroStar's FDA labeling, which governs insurance coverage for TMS therapy, uses the broader "failed to achieve satisfactory improvement from prior antidepressant medication" language.³

What the STAR*D trial taught us

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial — the largest naturalistic effectiveness study of antidepressants ever conducted — followed 4,041 outpatients with non-psychotic MDD through up to four sequential treatment steps.⁴ The findings reshaped how clinicians think about depression that does not respond to the first medication:

• After Step 1 (citalopram), the cumulative remission rate was approximately 33%.
• After Step 2 (switch or augmentation), cumulative remission rose to roughly 50%.
• After Step 3, cumulative remission reached approximately 60%.
• After Step 4 (the most aggressive switches), the cumulative remission rate was approximately 67%.

A 2023 reanalysis of STAR*D using the protocol-stipulated blinded HRSD measure (Pigott et al.) reported a substantially lower cumulative remission rate, closer to 35%.⁵ The original investigators have disputed the reanalysis methodology.⁶ The exact cumulative figure is therefore best understood as a range — but the central clinical implication is unchanged.

Two clinical implications follow. First, a substantial subgroup of patients remain symptomatic after four sequential medication trials — patients for whom serial monotherapy is not the answer. Second, the incremental benefit of each additional medication step diminishes: the second trial helps fewer patients than the first, and the fourth helps fewer than the third. This is the evidence base for escalating to neuromodulation earlier rather than later in patients who meet TRD criteria.

Why some depressions don't respond to medication

Major depressive disorder is heterogeneous. Two patients with identical PHQ-9 scores can have different underlying neurobiology, different stress-system reactivity, and different rates of medication metabolism. Several mechanisms appear to contribute to treatment resistance:

• Network-level dysfunction in the prefrontal cortex. Functional imaging consistently shows hypoactivity in the left dorsolateral prefrontal cortex (DLPFC) and altered connectivity with the subgenual cingulate in depressed patients — circuits that oral antidepressants influence only indirectly.⁷
• Pharmacogenomic variability. Cytochrome P450 polymorphisms can produce sub-therapeutic plasma levels at standard doses, or excessive levels and side-effect intolerance.
• Comorbidity load. Anxiety disorders, post-traumatic stress disorder, substance use, chronic pain, and inflammatory illness all reduce antidepressant response rates.
• Underlying bipolarity. A subset of "treatment-resistant" patients have unrecognized bipolar II — for whom antidepressant monotherapy is less effective and sometimes destabilizing.

A careful re-evaluation — confirming MDD vs. bipolar depression, screening for substance use and trauma history, and verifying that each prior medication trial was truly adequate in dose and duration — is the first step before escalating treatment.

Evidence-based options after two failed antidepressants

For patients who meet TRD criteria, multiple FDA-cleared options exist. They are not interchangeable; the choice depends on prior trial history, comorbidities, and patient preference:

• Transcranial magnetic stimulation (TMS). FDA-cleared since 2008 for adults with MDD who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.³ In a multisite naturalistic study of 307 patients with an average of 2.5 failed antidepressant trials in the current episode, response rates were approximately 58% and remission rates approximately 37%.⁸ TMS therapy is non-systemic, does not require anesthesia, and has no cognitive side effects.
• Esketamine (Spravato). FDA-approved intranasal NMDA-receptor antagonist for TRD — originally (2019) as an adjunct to an oral antidepressant, and since January 2025 also as monotherapy for TRD in adults. Administered under a REMS program with in-clinic observation.
• Augmentation with an atypical antipsychotic. Aripiprazole, brexpiprazole, and quetiapine XR have FDA approvals as adjunctive treatment in MDD with inadequate response to antidepressants.
• Lithium or T3 augmentation. Older evidence base; useful in selected patients.
• Electroconvulsive therapy (ECT). The most effective treatment for severe, melancholic, or psychotic depression; reserved for cases where rapid response is required or other options have failed.

Most major commercial payers and Medicare cover TMS for TRD when payer-specific documentation criteria are met. Coverage layers — benefit, medical-necessity criteria, and prior authorization — vary by carrier and plan. You can verify your insurance coverage before any scheduling commitment.

When to ask your psychiatrist about TMS

A reasonable trigger for the TMS conversation is: two adequate antidepressant trials in the current episode without remission. Earlier referral is appropriate in patients who have already exhausted multiple medications across prior episodes, who cannot tolerate antidepressant side effects, or for whom systemic medication exposure is contraindicated (for example, pregnancy planning).

Specific eligibility for TMS includes no personal history of seizure disorder, no ferromagnetic implants within roughly 30 cm of the treatment coil, and medical stability for outpatient daily treatment over six to nine weeks. A psychiatrist confirms candidacy and selects the protocol.

Key takeaways

• Treatment-resistant depression is a clinical specifier, not a separate diagnosis — applied to MDD when ≥2 adequate antidepressant trials in the current episode have failed.
• STAR*D documented that cumulative remission rates plateau near 67% after four medication steps, leaving roughly one-third of patients still symptomatic.
• Network-level prefrontal dysfunction, pharmacogenomic variability, comorbidity, and unrecognized bipolarity all contribute to non-response.
• Evidence-based options after two failed antidepressants include TMS, esketamine, atypical-antipsychotic augmentation, and — in severe cases — ECT.
• TMS is FDA-cleared, covered by major payers for TRD, and demonstrates approximately 58% response and 37% remission in real-world TRD cohorts.

If you live in Anaheim, Orange County, or the broader 30-mile radius and have completed two or more antidepressant trials without remission, our psychiatrists can review your history, confirm TRD criteria, and walk you through whether TMS therapy is appropriate. Most patients begin with a coverage check so the financial picture is clear before the clinical conversation.

Sources / Further reading